Ligand id: 8291

Name: safinamide

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 64.35
Molecular weight 302.14
XLogP 3.07
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Safinamide is approved as an adjunct to dopamine agonist or levodopa/carbidopa therapy in patients with Parkinson's disease experiencing "off" episodes.
Mechanism Of Action and Pharmacodynamic Effects
Safinamide's main action is to inhibit monoamine oxidase B (MAOB) which reduces degradation of dopamine [3], but may also inhibit reuptake of dopamine and act to inhibit glutamate release, and block sodium and calcium channels. Inhibition of MAOB effectively increases dopamine levels in the brain, providing some relief from the motor symptoms of Parkinson's disease. The drug helps to reduce the motor fluctuations which can occur when the effect of levodopa therapy wears off.
External links